The ICR works with our hospital partner The Royal Marsden across several centres to take the results of our research rapidly into the clinic, with the aim of developing better treatments for cancer patients.
The National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at The Royal Marsden and the ICR is the only BRC to specifically focus on cancer. Its aim is to drive pioneering, translational and clinical research.
Our aim is to promote cancer research, training, fundraising and infrastructure building in low and middle income countries.
This centre is a collaborative initiative between The Royal Marsden the ICR that aims to identify the molecular mechanisms that drive cancers and to target them with a new generation of treatments.
This virtual centre aims to increase communication between clinicians and scientists with an interest in translational immunotherapy. It brings together staff and students from the ICR and our partner hospital, the Royal Marsden.
The Drug Development Unit was opened in February 2005 as a joint unit of the ICR and The Royal Marsden. In 2011, at the Experimental Cancer Medicine Centre Network quinquennial review, the unit was given a rating of ‘outstanding’ for past work and future plans.
The Joint Department of Physics conducts and translates research and development of medical physics into clinical practice. It is a collaboration of academic and clinical staff from the ICR and The Royal Marsden.
Our pioneering research into diagnostics combines the power of digital pathology and artificial intelligence.
Our virtual research centre, a collaboration between The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, has been driving pioneering research for innovative treatments for sarcomas since our launch in January 2019.
Our Centre's goal is to develop novel treatments and diagnostic tests, and deliver changes in clinical practice, for children with cancer. We aim to do this through innovative clinical trials that are driven by our scientific understanding of children’s cancer mechanism.